New Development of DNA and mRNA Vaccines against Infectious Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 327
Special Issue Editor
2. Department of Infectious Diseases and Host Defense, Gunma University, Gunma, Japan
Interests: malaria; malaria vaccine; DNA vaccine; cancer; infectious disease
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Antibiotics and vaccines have been the most effective defense against pathogens since human beings first discovered “how to fight against infectious disease”. Vaccination technology is evolving day by day. Nucleotide-based vaccines, DNA vaccines and mRNA vaccines are the newest vaccine platforms, and the latest commercialized “mRNA vaccine” has been distributed all over the world as the “savior of COVID-19”. This vaccine is a game changer, but there is some concern regarding its need for deep-freezer storage. Compared with mRNA vaccines, DNA vaccines can be stored more stably.
This Special Issue will focus on “DNA vaccine and mRNA vaccine against Infectious Diseases”. It is not limited to original papers: review articles, new methodologies, concepts for new DNA or mRNA vaccines and next-generation vaccines against infectious diseases affecting humans, animals and plants are also welcome.
Dr. Takashi Imai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA vaccine
- mRNA vaccine
- infectious diseases
- adjuvants
- cellular immunity
- humoral immunity
- immunological memory.
